Kelly Drew, Chief Executive Officer of Be Cool Pharmaceutics promotes the science of hibernation and commercialization of hibernation-based therapies. Dr. Drew studied neuropharmacology at Mt. Sinai School of Medicine and at the Karolinska Institute before returning to Alaska in 1990 where she is now Professor of Chemistry and Biochemistry at the University of Alaska Fairbanks and directs a new NIH funded center in hibernation science. Passionate about the neurochemistry of consciousness and brain energy metabolism Dr. Drew fell in love with hibernation. Over the past 25 years, Dr. Drew’s research group discovered a mechanism necessary and sufficient to drive the onset of hibernation. She founded Be Cool Pharmaceutics LLC in 2015 to commercialize therapeutics for neurocritical care after cardiac arrest, and post-operative shivering. She consults with the space flight industry on human hibernation for long-term space travel.